Medicine relies heavily on diagnostic testing. Before the end of 2019 – the beginning of 2020, the modernized world took for granted accurate and available diagnostic tests. The COVID-19 pandemic taught the world, even the wealthiest countries, how fragile human health can become when tests are lacking. The assumption of available testing and the confidence in test results has been seriously challenged. With these challenges, Point-of-Care (PoC) tests has transgressed medicine and science to include politics, finance, and humanity at its core. This Bard senior project is rooted in the science of a proof-of-concept paper-based ELISA Immunodot assay for the detection of C-reactive protein (CRP). CRP can be identified at varying blood concentrations found in humans physiology and disease. CRP testing is used for clinical diagnoses millions of times per month in the United States. The results confirm that the ELISA Immunodot can both distinguish CRP+ and CRP- standards and semi-quantitively predict the CRP concentration of the standard. The ability to relate the intensity of the CRP colorimetric output to a standard CRP concentration has potential applicability in future medical testing
